- First in the life science industry to aggregate all interactive data from healthcare stakeholder interactions and life science company internal data sets to deliver AI-driven analytics on the trends, themes, and topics that matter.
- This therapeutic area insight management platform is designed to deliver the most accurate and comprehensive insights map to enable teams to better understand disease areas as they evolve.
- Virtual Science AI’s applied model approach enables life science companies to build disease area-specific AI where accuracy improves over time, compliantly learning through the company's lens while also maintaining confidentiality.
- The platform saves life science executives a significant amount of time and enables teams to respond more rapidly to trends strategically and tactically.
LONDON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Life science data can be highly disjointed and complex yet rich in potential insights. There are a variety of common insight-generation activities carried out with functional groups and through different channels; however, the findings are often disjointed and rarely connected.
Consequently, insights are frequently missed in all the information noise. This leads to the insights not being appropriately acted upon when they could help bring the right treatments to patients who need them.
Virtual Science AI provides AI-based solutions for immediate insights that are customisable to connect and combine various public and company data sets into one platform view. By doing this, we make sense of unstructured life science data and drive digital alignment to help teams better comprehend evolving disease areas in real time.
This solution is delivered through Virtual Science AI’s pharma-compliant first-in-class AI system, which ingests relevant data and concisely synthesises the information to support the identification of trends and themes. This well-organised information can then be efficiently shared across the enterprise, enabling teams to have a more positive impact on the product/disease area.
The team at Virtual Science AI is committed to helping improve the life science industry’s engagement with its external stakeholders and insight management teams. Headquartered in London and with operations in Europe, North America, Asia Pacific, and Latin America, Virtual Science AI creates cutting-edge software as a service (SaaS) and Artificial Intelligence solutions in the life-science and healthcare sectors. Notably, Virtual Science AI is trusted by 12 of the top 20 pharmaceutical companies and numerous leading biotechnology companies.
Tom Hughes, the CEO of Virtual Science AI, outlines the impact that the therapeutic area landscape analysis solution is already having:
“We have built a game-changing solution for therapeutic area landscape analysis. It frees up teams from highly manual analysis tasks, allowing them to spend more time responding to trends to have a positive effect faster.
“The therapeutic area analysis solution has already been deployed and validated by numerous leading pharmaceutical companies across different functions, and the feedback is very positive on the advantages gained.”
Chin Han Chen, Chief Technology Officer of Virtual Science AI and leading expert in the field of AI, added:
“We have developed a modular approach to AI models that is pharma-compliant, enabling us to seamlessly scale with new AI models and features. The models become more accurate to best serve different life science company therapeutic area landscape use cases.
“AI-driven insight-generation outperforms human-generated insights due to its reduced bias, resulting in superior accuracy.”
For further information about the Virtual Science AI therapeutic area landscape solution, visit: www.virtualscienceai.com.
About Virtual Science AI
Virtual Science AI is a global provider of external stakeholder interaction services in the pharmaceutical field, such as Advisory Boards and Panels and Insight Management solutions. The company leverages its technologies to effectively enhance engagement and insight-generation with stakeholders in R&D, Medical Affairs, Public Affairs, Pricing & Access, and Commercial life science company functions.
The ongoing goal of Virtual Science AI is to improve how relevant teams engage with their stakeholders and encourage the use of interaction outputs to improve critical decision-making at various stages of the product life cycle. This ultimately contributes to achieving the overall mission of these organisations— faster, more meaningful, and actionable insights for life science teams to help bring treatments to patients who need them at a more rapid pace.
Media Contact
Virtual Science AI
Andrew Donlon, Global Marketing Lead
United Kingdom, London
+44 (0)7919 172226
Andrew.donlon@virtualscienceai.com
www.virtualscienceai.com
